Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. (TARS) director David E. I. Pyott reported the settlement and exercise of 201 Restricted Stock Units, each converting into one share of common stock, on September 15, 2026. The 201 resulting shares are held indirectly through the David E. I. Pyott Trust, which now holds 9,575 common shares. Following the transaction, Pyott also holds 605 RSUs, which vest in equal installments on September 15, 2026, December 15, 2026, March 15, 2027 and June 15, 2027, subject to continuous service as a non-employee director. The filing states that 1,383 of the trust’s shares were previously held directly and transferred to the trust with no change in Pyott’s pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Tarsus Pharmaceuticals, Inc. (TARS) reported that director Wendy L. Yarno exercised 302 Restricted Stock Units (RSUs) on September 15, 2026, settling them into 302 shares of common stock. The RSU award was granted for service as a non-employee director, and no Rule 10b5-1 trading plan is indicated.
After this exercise, Yarno holds 16,956 shares of common stock directly and 907 RSUs directly. Each RSU represents a contingent right to receive one share of Tarsus common stock, vesting in equal installments through June 15, 2027, subject to continuous board service.
Tarsus Pharmaceuticals, Inc. director William J. Link reported an exercise of 201 Restricted Stock Units into 201 shares of common stock on September 15, 2026, leaving 605 RSUs outstanding. On the same date he reported sales of 12,500 common shares at weighted average prices around the high-$70s under a Rule 10b5-1 trading plan adopted on September 8, 2025.
Tarsus Pharmaceuticals, Inc. (TARS) received a notice under Rule 144 that director J. Link plans to sell 12,500 shares of common stock through Merrill Lynch on or about September 15, 2026 on Nasdaq. The shares were acquired on January 10, 2017 via a stock option exercise paid in cash.
Tarsus Pharmaceuticals, Inc. (TARS) completed its acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, merging Apex 2026 Merger Sub into Alkeus, which now operates as a wholly owned subsidiary. Tarsus paid $270,000,000 in up-front cash, subject to customary and post-closing adjustments, and issued 2,908,692 shares of common stock as additional up-front consideration to Alkeus equityholders.
Alkeus holders are also eligible for up to $350,000,000 in future milestone payments, including $250,000,000 payable in cash and/or Tarsus common stock upon U.S. regulatory approval of an Alkeus product, and $100,000,000 in cash upon the first U.S. sale of an Alkeus product, plus tiered low-to-mid single-digit revenue sharing on future annual worldwide gildeuretinol (ALK-001) net sales. Tarsus gains worldwide rights to ALK-001, an oral Phase 3 investigational therapy for Stargardt disease, which has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA and is being studied in the NORTHSTAR Phase 3 trial with topline data anticipated in 2029.
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock on September 4, 2026 in transactions reported as sales in the open market or in private transactions. The sales were executed under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025, at weighted average prices of about $90.27 and $91.27 per share, with individual trades in ranges from $90.00 to $90.91 and from $91.06 to $91.45. Following these transactions, he is reported to hold 33,421 shares of common stock directly.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold an aggregate of 13,953 shares of common stock on September 4, 2026. The sales included both directly held shares and shares held through a spouse’s Roth IRA, and were executed in the open market under pre-arranged Rule 10b5-1 trading plans adopted on May 29, 2026 and June 1, 2026. Following these transactions, an additional 12,040 shares of common stock are reported as indirectly held through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Operating Officer Neervannan Seshadri sold 4,564 shares of common stock on September 4, 2026 at $85.00 per share in an open-market transaction effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following this sale, he directly holds 78,532 shares and is also reported with an indirect balance of 475 shares related to his daughter, for which beneficial ownership is disclaimed.
Tarsus Pharmaceuticals, Inc. (TARS) has an officer, Bobak Azamian, filing a Form 144 notice covering a potential sale of up to 10,000 shares of common stock through Merrill Lynch on Nasdaq. These shares were acquired on January 13, 2017 in a private placement. In the prior three months, the Bobak Azamian Living Trust reported two sales of 10,000 shares each.
Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice indicating an intention to sell restricted or control securities. The notice covers a planned sale of 3,180 shares of Tarsus common stock through Fidelity Brokerage Services LLC on Nasdaq. The filing states that the shares are in the account of Stephen H. Lin, the spouse of company officer Elizabeth Yeu-Lin. It also notes prior sales from the same account over the past three months and lists 43,882,996 Tarsus common shares outstanding as of September 4, 2026.